An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults

Trial Profile

An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2018

At a glance

  • Drugs JNJ 64400141 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 22 May 2018 Planned primary completion date changed from 22 May 2018 to 10 Jul 2018.
    • 04 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 22 May 2018.
    • 31 Jan 2018 Planned End Date changed from 31 Aug 2018 to 30 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top